^
Association details:
| Biomarker: | MSI-H/dMMR |
|---|---|
| Cancer: | Esophageal Adenocarcinoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
08/29/2023
Excerpt:
Esophageal and Esophagogastric Junction Cancers: Adenocarcinoma…Preferred Regimens…MSI-H/dMMR tumors (independent of PD-L1 status)…Fluoropyrimidine (fluorouracil or capecitabine), oxaliplatin, and nivolumab…
Secondary therapy:
5-fluorouracil + oxaliplatin; capecitabine + oxaliplatin
Title:
ONO Receives Approval of Opdivo® (Nivolumab) for Additional Indications of Unresectable Advanced or Recurrent Esophageal Cancer, and MSI-High Unresectable Advanced or Recurrent Colorectal Cancer in Japan for a Partial Change in Approved Items of Manufacturing and Marketing Approval
Excerpt:
Ono Pharmaceutical Co., Ltd....and Bristol-Myers Squibb...announced today that ONO received approval of Opdivo® (generic name: nivolumab) Intravenous Infusion (“Opdivo”), a human anti-human programmed cell death-1 (PD-1) monoclonal antibody in Japan for the following two additional indications, for a partial change in approved items of the manufacturing and marketing approval:...Microsatellite instability high (MSI-High) unresectable advanced or recurrent colorectal cancer that has progressed following chemotherapy...
Source:
Title:
A Phase Ib Trial to Evaluate the Safety and Efficacy of FMT and Nivolumab in Subjects With Metastatic or Inoperable Melanoma, MSI-H, dMMR or NSCLC
Excerpt:
...Subjects with a documented B-Raf (BRAF) mutation must have received the appropriate targeted therapy For MSI-H/dMMR patients -Histologically confirmed MSI-H/d...
Trial ID:
